Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.52 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.52 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.52 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786690 | 0.92 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL2717170 | 0.92 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL2721618 | 0.92 | PIK3CD (0.54) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL8486983 | 0.91 | PIK3CD (0.57) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL6122982 | 0.90 | PIK3CD (0.49) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL3777170 | 0.90 | PIK3CD (0.55) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL6127707 | 0.90 | PIK3CD (0.44) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL3788051 | 0.89 | PIK3CD (0.60) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL8476282 | 0.89 | PIK3CD (0.45) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 | |
| SCHEMBL8475319 | 0.87 | PIK3CD (0.50) | PIK3CDPIK3CBPIK3CGPIK3CACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312175-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2018-04-25 | — | — | EP | disclosed |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
| US-8765768-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765768-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765768-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130231352-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231352-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231352-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-09-05 | — | — | US | disclosed |
| WO-2012068343-A1 | QUINOLINE DERIVATIVES AS PIK3 INHIBITORS | AMGEN INC. (US) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | WEE2, WEE1, ITK | PIK3CD 14/4885PIK3CB 23/4885PIK3CG 19/4885 |
| US-20130231352-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, SSB | PIK3CD 4115/4885PIK3CB 4221/4885PIK3CG 4638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.